Training neural circuits early in development improves response, study finds – University of Illinois News

CHAMPAIGN, Ill. When it comes to training neural circuits for tissue engineering or biomedical applications, a new study suggests a key parameter: Train them young.

Techniques for training engineered neural circuits usually involve training them after the cells have fully matured. Using light-sensitive neurons derived from mouse stem cells, researchers at the University of Illinois, Urbana-Champaign found that training them throughout early cell development and network formation led to lasting improvements in the connections, responsivity and gene expression of the resulting neural network. They published their results in the journal Scientific Reports.

Its like an old dog learning new tricks versus a young puppy, said graduate student Gelson Pagan-Diaz, the first author of the study. When were training a network, if we stimulate it when its still like a puppy, we can get a better response to the training than if it were already mature.

Improved neural training has many applications in bioengineering and regenerative medicine. For example, the Illinois team hopes to use trained neural circuits to control the movement and behavior of miniature bio-hybrid machines. The types of improvements yielded by early training could give the machines and circuits more functionality and give the researchers more precise control over those functions.

As we advance the field of building machines with living cells, being able to stimulate and program neuronal cells and networks with light early in their development could be an important tool in our engineering repository, said study leader Rashid Bashir, a professor of bioengineering and dean of the Grainger College of Engineering at Illinois. Furthermore, this work could have implications for developmental biology, regenerative medicine and brain research.

To train the neurons, the researchers used timed pulses of light to stimulate the cells. The researchers began the training regimen when the cells were early in their development clusters of stem cells, called embryoid bodies, primed to become motor neurons. They continued the training as the cells differentiated, becoming fully mature neurons, and further continued it after transferring the cells to plates to connect and form neural circuits.

They then compared the early trained circuits with those cultured first and trained later the usual method.

The researchers saw a number of differences between the groups, Pagan-Diaz said. In the neurons trained during development, they saw more extensions indicating connections between cells, an increase in neurotransmitter packages sent between cells, and more structured nerve firing, indicating greater network stability. The effects of the early training were long-lasting, whereas cells trained later tended to have transient responses.

You can think of the neurons being like athletes in training, Pagan-Diaz said. The light stimulation was like a regular workout for the neurons they were stronger and more athletic, and did their jobs better.

To determine the underlying basis for these changes, the researchers analyzed the neurons genetic activity. They saw an increase in gene expression for genes related to network maturity and neural function, indicating that the early training could have permanently altered genetic pathways as the cells developed, Bashir said.

The researchers are continuing to explore what kinds of activities could be enhanced or programmed by early neuron training in the embryoid body phase. Embryoid bodies could be useful building-block components for biological machines, Pagan-Diaz said, and also hold promise for regenerative medicine.

Previous studies have shown that embryoid bodies with motor neurons implanted into mice that had been injured could improve the regeneration of tissue, Pagan-Diaz said. If we can improve or enhance the functionality of these embryoid bodies prior to putting them into an injured model, then theoretically we could enhance the recovery beyond what has been seen with injecting them and then stimulating them later.

The National Science Foundation supported this work through the Emergent Behaviors of Integrated Cellular Systems science and technology center and through the Miniature Brain Machinery Research Traineeship. Research staffer Jenny Drnevich, graduate students Karla Ramos-Cruz and Richard Sam, and University of Illinois, Chicago bioengineering professor Perijat Sengupta were co-authors of the paper.

See more here:
Training neural circuits early in development improves response, study finds - University of Illinois News

Cord blood offers hope for rare diseases and ethnic minorities – The Province

A different combination of chemotherapy drugs together with umbilical cord blood may result in a safer, more universal treatment for a variety of genetic disorders. emarys / iStock / Getty Images Plus

Researchers at the University of Pittsburgh Medical Centre may have developed an innovative method of transplanting stem cells, resulting in a safer, universal treatment for a variety of genetic disorders. Through combining this approach with umbilical cord blood, treatment is also more accessible to ethnic minorities, a demographic that historically has had difficulties accessing bone marrow transplants.

The study, published in Blood Advances and the largest of its kind to date, used umbilical cord blood to treat 44 children with varying non-cancerous diseases. Umbilical cord blood is a potent source of hematopoietic stem cells cells that are able to form red and white blood cells in the patients. Due to their ability to develop into different types of cells, this treatment can be used to address many different types of disorders.

We wanted to offer a uniform concept to a wide array of diseases, said Dr. Paul Szabolcs, the Chief of Bone Marrow Transplantation and Cellular Therapies at UPMC Childrens Hospital and principal author of the study. We successfully reduced the intensity of chemotherapy and nevertheless, we were still able to engraft all our patients.

Typically, before receiving a stem cell graft (either umbilical cord blood or bone marrow) patients undergo an intense round of chemotherapy to kill off the patients own immune system and allow the new cells to grow. This method is effective but damaging to the body. For patients who do not have cancer and are pursing this treatment to improve the quality of their life (versus saving their life), the risks may simply be too high.

The approach developed by the team at the Pittsburgh Medical Centre uses a different combination of chemotherapy drugs, which are not as potent to the body. The goal of this approach is not to kill every cell in the patients bone marrow, but to make enough room for the new cells to flourish.

We successfully reduced the intensity of chemotherapy and we were still able to engraft all our patients, says Szabolcs. Using maximum intensity, you might be inadvertently killing patients and causing irreversible organ disease. [We used] use reduced intensity and have excellent survival.

This more moderate procedure is promising for conditions where the standard intensity regime poses a barrier to bone marrow or cord blood transfusions. More than half of the patients in the study had a form of leukodystrophy a genetic disorder that leads to the destruction of the protective coating of the nerves in the brain and spinal cord, according to the National Organization for Rare Disorders.

Three year survival rate after the standard chemotherapy preparation for umbilical cord blood transfusions for individuals with leukodystrophies ranges from 49 per cent to 77 per cent depending on their health at the time of the transfusion. The reduced-intensity approach reported a three year survival rate of 94 per cent.

The stem cells in umbilical cord blood provide a promising treatment as recipients do not have to have a perfect HLA (immune profile) match with the donor.

About 70 per cent of patients who need stem cells or bone marrow transplants have to rely on an unrelated donor to find a match, according to the University of British Columbia Medical Journal. This can create accessibility concerns for ethnic minorities. A 2012 study calculated that match rates for unrelated donors ranges from two per cent for POC to 46 per cent for Caucasians.

Since 2012, Canadian Blood Services has extended campaigns to communities with low match rates to increase the presence of donors. The concern still remains, however. Cord blood offers a hopeful alternative.

Its really applicable for ethnic minorities where the perfect HLA match might be elusive in the living donor population, says Szabolcs. And cord blood is readily available.

emjones@postmedia.com |@jonesyjourn

Dont miss the latest on COVID-19, reopening and life. Subscribe to Healthings daily newsletterComing Out of COVID.

Read more here:
Cord blood offers hope for rare diseases and ethnic minorities - The Province

National STEM Scholars Announced for 2020 – PR Web

The 2020 Class of National STEM Scholars convened at Gatton Academy at WKU this week

LOUISVILLE, Ky. (PRWEB) August 06, 2020

Nine middle school teachers from eight states have been selected to participate in the prestigious National STEM Scholar Program, a unique professional development program that provides advanced STEM (science, technology, engineering and math) training, national network building, and project support for middle school science teachers nationwide.

Created in partnership between the National Stem Cell Foundation and The Gatton Academy of Mathematics and Science at Western Kentucky University (WKU), the National STEM Scholar Program selects ten teachers each year from a national pool of applicants based solely on the description of a Challenge Project the applicant would implement if funds were not a barrier to execution. Selected projects are chosen for maximum impact in the middle school classrooms where research shows lifelong STEM career decisions are being made. STEM Scholars convene on WKUs campus for a week of advanced STEM training and finalize their Challenge Projects with input from their National STEM Scholar class colleagues. Each Scholar is provided access to a generous stipend for the technology and supplies they need to implement their Challenge Projects at home.

The 2020 National STEM Scholar class will be hosted by The Gatton Academy August 4 - 9 on the campus of WKU in Bowling Green, KY. Selected from approximately 200 applicants across the country, the 2020 National STEM Scholars are:

Dr. Paula Grisanti, CEO of the National Stem Cell Foundation, said, Through our work with researchers and scientists nationwide, we became aware of the widening gap between 21st Century jobs and the U.S. STEM-educated graduates who can fill them. We added education to our mission in 2015 as a way to support the development of a new generation of scientists working to advance technology, build infrastructure and find cures for diseases and conditions that affect us all. Supporting teachers who inspire and motivate middle school students at this critical decision-making age will directly impact how many choose to pursue STEM skills that are essential for 21st Century jobs. By investing in the influential middle school STEM teacher now, we reach thousands of students in classrooms today and far into the future.

Dr. Julia Link Roberts, Executive Director of The Gatton Academy, added, This partnership will accrue benefits for the National STEM Scholars, middle school students in their classrooms, and the middle school science teachers with whom they collaborate. The National STEM Scholar Program is an excellent way for teachers to learn new strategies and new ways to engage students to help them become and stay interested in science and math.

To date, National STEM Scholars represent 49 middle schools in 26 states, from Alaska to New York and Wisconsin to Florida. A significant requirement of selection is the commitment to share lessons learned with colleagues in the Scholars home schools, districts or states, magnifying impact over multiple classrooms and years.

About the National Stem Cell Foundation The National Stem Cell Foundation is a 501(c)3 non-profit organization that funds adult stem cell and regenerative medicine research, connects children with limited resources to clinical trials for rare diseases and underwrites the National STEM Scholar Program for middle school science teachers inspiring the next generation of STEM (science, technology, engineering and math) pioneers nationwide. For more information, visit http://www.nationalstemcellfoundation.org.

About The Gatton Academy Established in 2007, The Gatton Academy of Mathematics and Science is Kentuckys first state-supported, residential program for high school students with interests in advanced math and science careers. One of only 15 such programs in the nation, The Academy has been named to The Washington Posts list of top-performing schools with elite students for eight consecutive years. For more information, visit http://www.wku.edu/academy.

Share article on social media or email:

See the rest here:
National STEM Scholars Announced for 2020 - PR Web

US government considers ethics of aborted tissue research – Catholic News Agency

Washington, D.C. Newsroom, Aug 6, 2020 / 12:00 pm MT (CNA).- A new federal ethics advisory board for fetal tissue research has convened to consider future federally-funded research proposals that involve tissue from aborted babies.

The Human Fetal Tissue Research Ethics Advisory Board of the National Institutes of Health (NIH) met for the first time on July 31, to advise the Health Secretary on the ethics of research proposals involving fetal tissue of aborted babies.

The board was first announced in June of 2019, when the Trump administration decided to halt new research with aborted fetal tissue at NIH facilities, and limited funding of such research conducted outside the NIH.

For the research conducted outside the NIH, or extramural research, the administration announced that an ethics advisory board would be appointed to consider such funding and advise the secretary of Health and Human Services (HHS) on the proposals.

Some researchers have called for the administration to end its moratorium, saying that research with aborted fetal tissue could be vital to developing treatments and a cure for the new coronavirus (SARS-CoV-2).

In February, the HHS announced that it would begin accepting nominations to the board, and during that time period, some researchers at an NIH research laboratory told the Washington Post that the administrations moratorium on fetal tissue research was hindering possible advances in research on treatments for the coronavirus.

Dr. David Prentice, now a member of the NIH Human Fetal Tissue Research Ethics Advisory Board, told CNA in March that the timing of the comments was peculiar as it could have been related to the consideration of appointments to the board.

Several leading coronavirus vaccine candidates are using cell lines from aborted babies, including some funded by the U.S.; other candidates have been determined to be ethically uncontroversial by the pro-life Charlotte Lozier Institute.

One candidate in particularbeing developed by Moderna and the National Institute of Allergy and Infectious Diseasesis not using fetal cell lines directly in production, but is based on research that involved aborted fetal cell lines. As Moderna was not involved in that research, CLI said that the vaccine candidate is ethically uncontroversial.

The NIH ethics board members are appointed for a duration that lasts as long as the board is convened; the boards charter says that [t]he estimated annual person-years of staff support required is 0.7. Appointments to the board are made by the HHS secretary.

Heading the advisory board is Paige Cunningham, interim president of Taylor University, an evangelical Christian university in Indiana.

Several Catholic bioethicists are on the board, including Fr. Tadeusz Pacholczyk, director of education at the National Catholic Bioethics Center. The co-chair of the Catholic Medical Association (CMA) ethics committee, Greg Burke, is a member, along with CMA member Dr. Ashley Fernandes of the Ohio State University medical school.

The pro-life Charlotte Lozier Institute (CLI) is also represented on the board, with CLI vice president Dr. David Prentice and associate scholars Ingrid Skop and Maureen Condic as members.

Some board members, such as Dr. Lawrence Goldstein of the University of California San Diego, support fetal tissue research; he called cell lines from fetal tissue critical in vaccine development, along with stem cell research and the use of humanized mice to develop immune cell-forming tissues.

Two members testified in 2016 before the House select investigative panel of the Energy and Commerce Committee, in a hearing on bioethics and fetal tissue.

Cunningham said at the hearing that [t]he fetus is a human subject entitled to the protections that both traditional and modern codes of medical ethics provide to human subjects.

Kevin Donovan, MD, director of the Pellegrino Center for Clinical Bioethics at Georgetown University Medical Center, also testified, noting the current moral ambiguity in the nations discourse on abortion.

We have decided that we can legally abort the same fetus that might otherwise be a candidate for fetal surgery, even using the same indications as justification for acts that are diametrically opposed, he said. We call it the fetus if it is to be aborted and its tissues and organs transferred to a scientific lab. We call it a baby, even at the same stage of gestation, when someone plans to keep it and bring it into their home.

If we cannot act with moral certainty regarding the appropriate respect and dignity of the fetus, we cannot morally justify its destruction, he said.

During the public portion of the July 31 meeting, board members were introduced and then heard from several researchers who were either in support of or in opposition to research using fetal tissue from elective abortions.

The 2008 Vatican document Dignitatis Personae addressed the topic of aborted fetal tissue research, saying that there is a duty to refuse to use such biological material even when there is no close connection between the researcher and the actions of those who performed the artificial fertilization or the abortion, or when there was no prior agreement with the centers in which the artificial fertilization took place.

This duty springs from the necessity to remove oneself, within the area of ones own research, from a gravely unjust legal situation and to affirm with clarity the value of human life, the Congregation for the Doctrine of the Faith document stated.

Read this article:
US government considers ethics of aborted tissue research - Catholic News Agency

Cell Viability Assays Market by Production Analysis, Current Trends 2024 Analysis of Regions with Top vendors, Market Dynamics, Types, Applications,…

Market Challenge: Threats in major regions

Cell Viability Assays Market Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/15398351

Cell Viability Assays Market Segmentation Covers:

Product: o Consumables

o Instruments

Regional Segmentation:

The objective of Studies:

Purchase this Report (Price 2500 USD for single-user license) https://www.industryresearch.co/purchase/15398351

Some Points from Cell Viability Assays Market Report TOC:

PART01:EXECUTIVESUMMARY

PART02:SCOPEOFTHEREPORT

PART03:MARKETLANDSCAPE

PART04:MARKETSIZING

PART05:FIVEFORCESANALYSIS

PART06:MARKETSEGMENTATIONBYTECHNOLOGY

PART07:MARKETSEGMENTATIONBYFURNACETYPE

PART08:CUSTOMERLANDSCAPE

PART09:GEOGRAPHICLANDSCAPE

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

For Detailed TOC Click Here

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Nanomaterials in Cosmetic and Personal Care Market Growth Size, Share 2020 | Industry Analysis with COVID-19 Impact, Company Overview, Key Countries with Future Prospect to 2026

Needle-Free IV Connectors Market Size Outlook 2020 to 2025: Market Trends, Segmentation, Growth Rate and Competitive Landscape with COVID-19 Outbreak

Automated Material Handling and Storage System Market 2020| Worldwide Overview by Industry Size, Market Share, Future Trends, Growth Factors and Leading Players Research Report Analysis till 2025

Non-dairy Creamer Fats Market Growth Trends with Key Players 2020 Size by Regions, Global Industry Share, Sales Revenue and Opportunities till 2026 with COVID-19 Impact

Petroleum Jellies Market 2020 Global Industry Size Estimation, Research Update, Future Scope, Revenue, Pricing Trends, Growth Opportunity, Regional Outlook and Forecast to 2025

Toy Balloon Market Size | Share Forecast 2020 to 2026: Competition Analysis, Industry Growth by New Innovations, Top Players Analysis with COVID-19 Impact

Here is the original post:
Cell Viability Assays Market by Production Analysis, Current Trends 2024 Analysis of Regions with Top vendors, Market Dynamics, Types, Applications,...

New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 – GlobeNewswire

August 06, 2020 09:00 ET | Source: Alliance for Regenerative Medicine

Cell, Gene & Tissue-Based Therapy Developers Poised to Break Year-Over-Year Global Financing Records

WASHINGTON, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announces the publication of its H1 2020 Global Sector Report, Innovation in the Time of COVID-19. The report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic.

As the voice of the sector globally, ARM regularly publishes sector data reports to showcase clinical and scientific progress, as well as advancements and remaining challenges in the policy environment surrounding cell, gene and tissue-based therapies. The report also includes updated metrics on fundraising and clinical trials from more than 1,000 therapeutic developers worldwide.

Highlights from the H1 2020 Global Sector Report include:

Janet Lambert, CEO of ARM, commented:The regenerative medicine and advanced therapy sector has shown remarkable resilience in the face of many new challenges posed by COVID-19. Most importantly, were continuing to see patients benefit from the profound therapeutic effects of both approved products and those currently in clinical development. ARM will continue to work with our membership and with policymakers in the second half of 2020 to further advance these transformative technologies. We are committed to bringing these life-changing therapies to patients in need.

This report is the latest in ARMs series of global regenerative medicine sector reports, providing up-to-date metrics on financings and the clinical landscape, as well as expert commentary on key trends and progress in the field. The full report is availableonline here, with key sector metrics and infographicsavailable here. For more information, please visitwww.alliancerm.orgor contact Kaitlyn (Donaldson) Dupont atkdonaldson@alliancerm.org.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory and reimbursement initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing regenerative medicines and advanced therapies. In its 11-year history, ARM has become the voice of the sector, representing the interests of 360+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. To learn more about ARM or to become a member, visithttp://www.alliancerm.org.

Excerpt from:
New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 - GlobeNewswire

Contract Manufacturing Services market for stem cells is expected to be worth over USD 2.5 billion by 2030, claims Roots Analysis – Market Research…

Driven by a robust and growing pipeline of stem cell therapies, the demand for development and manufacturing services for such advanced product candidates is anticipated to increase beyond the capabilities of innovator companies alone

Roots Analysis has announced the addition of the Stem Cell Contract Manufacturing Market, 2019-2030 report to its list of offerings.

Owing to a highly regulated production environment and the need for state-of-the-art technologies and equipment, it is difficult for innovators to establish in-house expertise for the large-scale manufacturing of stem cell therapies. As a result, stem cell therapy developers are increasingly relying on contract manufacturing organizations (CMOs) for their product development and manufacturing needs.

To order this 300+ page report, which features 120+ figures and 145+ tables, please visit this link

Over 80 CMOs presently claim to provide manufacturing services for stem cells therapies The market landscape is fragmented, featuring a mix of companies of all sizes; however, small and mid-sized companies represent 70% of the overall number of industry stakeholders. It is worth highlighting that over 50% of the CMOs claim to be capable of accommodating both clinical and commercial scales of operation.

100+ strategic alliances have been inked since 2015 In fact, nearly 60% of the abovementioned deals were established post 2016. Majority of these agreements were observed to be focused on the manufacturing of various types of stem cells. It is worth highlighting that the maximum number of partnerships related to stem cell therapies were reported in 2018.

More than 80,000+ patients were reported to have been enrolled in stem cell therapy related trials, since 2010 As a result, the manufacturing demand for such therapies can be anticipated to grow significantly over the next decade. The report features detailed projections of the future clinical and commercial demand for stem cell manufacturing, based on parameters, such as target patient population, dosing frequency, dose strength, source of stem cells, type of stem cells and key geographies.

Currently, there are more than 100 facilities dedicated to stem cell manufacturing The maximum share of the installed capacity belongs to large (more than 1,000 employees) and very large (more than 5,000 employees) companies. The report provides a detailed capacity analysis, taking into consideration the reported manufacturing capacities of industry stakeholders, and offering estimates on the distribution of the global contract manufacturing capacity for stem cell therapies, by company size, scale of operation and geography.

By 2030, North America and Europe are anticipated to capture over 70% of the market share Overall, the market is anticipated to witness an annualized growth rate of more than 20% over the next decade. In the long-term, the opportunity is expected to be well distributed across key stakeholder companies, which offer services for a diverse range of allogenic and autologous stem cell therapies.

To request a sample copy / brochure of this report, please visit this link

The USD 2.5 billion (by 2030) financial opportunity within the stem cells contract manufacturing market has been analyzed across the following segments:

The report features inputs from eminent industry stakeholders, according to whom the contract manufacturing opportunity related to stem cell therapies can be expected to witness substantial growth due to the rising demand for regenerative medicine across a number of therapeutic areas. The report includes detailed transcripts of discussions held with the following experts:

The research covers detailed profiles of key players (illustrative list provided below) from across key global markets (North America, Europe and Asia-Pacific); each profile provides an overview of the company, information on its service portfolio, manufacturing facilities, financial performance (if available), details on recent developments, as well as an informed future outlook.

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/stem-cell-therapy-contract-manufacturing-market-2019-2030/271.html

or email [emailprotected]

You may also be interested in the following titles:

Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 [emailprotected]

Link:
Contract Manufacturing Services market for stem cells is expected to be worth over USD 2.5 billion by 2030, claims Roots Analysis - Market Research...

Gene Therapy Market By Industry Type, By Brand And Major Players 2020-2027 – Market Research Posts

The report covers the forecast and analysis of the gene therapy market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the gene therapy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the gene therapy market on a global level.

In order to give the users of this report a comprehensive view of the gene therapy market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are bench marked based on their market size, growth rate, and general attractiveness.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10170423

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the gene therapy market by segmenting the market based on the type, vector type, therapy area, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Gene therapy is utilized for treating neurodegenerative disorders like Alzheimer, amyotrophic lateral sclerosis, and spinal muscular atrophy. Gene therapy is one of the key treatment kinds that will propel the market growth over the forecast period. Moreover, gene therapy also finds lucrative applications in precision medicine. In addition to this, a rise in the occurrence of cancer is prompting the demand to treat the disease through gene therapy.

Request For Full Report:https://www.kennethresearch.com/sample-request-10170423

Based on the type, the market can be segregated into Germ Line Gene Therapy and Somatic Gene Therapy. In terms of vector type, the gene therapy industry can be divided into Viral Vectors, Non-Viral Vectors, and Human Artificial Chromosome. On the basis of therapy area, the market for gene therapy can be classified into Cancer, Neurological Diseases, Infectious Diseases, Genetic Disorders, Rheumatoid Arthritis, and Others.

The key players included in this market are Advanced Cell & Gene Therapy, Audentes Therapeutics, Benitec Biopharma, Biogen, Blubird Bio, Inc., Bristol-Myers Squibb Company, CHIESI Farmaceutici SPA, Eurofins Scientific, Geneta Science, Genzyme Corporation, Gilead, GlaxoSmithKline PLC, Human Stem Cells institute, Novartis AG, Orchard Therapeutics, Pfizer Inc., Sangamo therapeutics, Spark therapeutics, and Voyager Therapeutics.

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

Read more:
Gene Therapy Market By Industry Type, By Brand And Major Players 2020-2027 - Market Research Posts

Stem Cell Assay Market Study for 2020 to 2027 providing information on Key Players, Growth Drivers and Industry challenges – Bulletin Line

COVID-19 can influence the global economy in three ways: by directly influencing production and demand, by creating supply chain and market disruptions, and by having a financial impact on businesses and financial markets. The eruption of COVID-19 has implications for many aspects such as flight cancellations. Travel bans and quarantines; Restaurants closed; all Indoor Events restricted; over forty countries declared a state of emergency; massive supply chain slowdown; stock market volatility; falling business confidence, growing panic in the population and uncertainty about the future.

This report examines the global Stem Cell Assay Market and analyses and examines the Stem Cell Assay Market development status and forecast in the US, EU, Japan, China, India and Southeast Asia. This report focuses on the highest players in the global Stem Cell Assay Market .

Ask For Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24266&utm_source=BLN&utm_medium=001

The scope of the report covers all major system technologies currently being implemented in the global Stem Cell Assay Market industry. Market values are supported the Top User (public and private) supports the production of Stem Cell Assay Market systems. Stem Cell Assay Market manufacturers place orders as soon as they receive work orders from Stem Cell Assay Market operators. Therefore, market figures are derived from the perspective of the top users taking into account their orders (Stem Cell Assay Market operator) for the Stem Cell Assay Market .

The Stem Cell Assay Market was created on the basis of an in-depth market analysis with contributions from industry experts. The report covers the growth prospects in the coming years and the discussion of the main providers.

Market drivers

Increasing deforestation due to increasing demand for increasing raw materials

For a full, detailed list, see our report

Market Challenge

Risks associated with the use of Stem Cell Assay Market

For a full, detailed list, see our report

Market Trend

Increasing consumer preference for Stem Cell Assay Market For a full, detailed list, see our report

The global market research report of Stem Cell Assay Market industry 2020 is distributed over several pages and contains exclusive Statistics, data, information, Stem Cell Assay Market trends and details of the competitive landscape in this niche sector.

To understand how the effects of COVID-19 are addressed in this report. A sample copy of the report is available at https://www.verifiedmarketresearch.com/product/Stem-Cell-Assay-Market/?utm_source=BLN&utm_medium=001

The report also focuses on the worlds leading industry players in the global Stem Cell Assay Market , providing information such as company profiles, product images and specifications, capacity, production, price, cost, revenue and contacting information. In addition, upstream raw materials and equipment as well as downstream demand analyses are managed. The global Stem Cell Assay Market development trends and market channels are analyzed. Finally, the feasibility of the latest investment projects is evaluated and general research results are offered. With tables and figures to help analyze the global Stem Cell Assay Market , this study provides important statistics on the state of the industry and can be a valuable guide and guidance for companies and individuals who are curious about the market.

Verified Market Researchis a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Mr. Edwyne Fernandes

US: +1 (650)-781-4080 UK: +44 (203)-411-9686 APAC: +91 (902)-863-5784 US Toll-Free: +1 (800)-7821768

Email:[emailprotected]

Read more here:
Stem Cell Assay Market Study for 2020 to 2027 providing information on Key Players, Growth Drivers and Industry challenges - Bulletin Line

Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth – GlobeNewswire

August 06, 2020 07:00 ET | Source: https://immatics.com/

Houston, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) --

Houston, Texas, August 6, 2020 Immatics N.V. (NASDAQ: IMTX; Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced the extension of its cell therapy manufacturing collaboration with The University of Texas Health Science Center at Houston (UTHealth), in Houston, Texas. The continued collaboration grants Immatics access to UTHealths state-of-the-art cGMP manufacturing infrastructure at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory, enabling continued production and supply of Immatics specialized, cell-based product candidates for testing in multiple clinical trials. Maximum capacity of the facility is anticipated at 48 ACTengine T cell products per month. The new agreement will run until the end of 2024. Under the agreement, UTHealth will provide Immatics with exclusive access to three cGMP suites and support areas for the manufacturing of various Adoptive Cell Therapy (ACT) products. Therapeutic T cell production will be carried out by Immatics manufacturing personnel and will be supported by a UTHealth-Immatics joint quality team.

Steffen Walter, Ph.D., Chief Technology Officer at Immatics, commented: During the last five years, we have established a strong and productive partnership with UTHealth that has enabled the initiation of four ongoing clinical trials. As we remain focused on the development of our clinical pipeline, this extension of our collaboration with UTHealth will fulfill Immatics manufacturing needs for our early-stage ACT clinical programs for the next four years. Being able to rely on a partner with profound cell therapy expertise who is familiar with our technologies and can support cGMP cell therapy production is critical to ensuring the advancement of our clinical trials. We look forward to continuing this fruitful collaboration with the experts at UTHealth.

Fabio Triolo, D.d.R., M.Phil., Ph.D., The Clare A. Glassell Distinguished Chair and Director of the Cellular Therapy Core at UTHealth, added: Signing the extended contract with Immatics fits into our strategy at UTHealth of supporting the development of new treatments for patients in need. We therefore look forward to continuing our collaboration and further leveraging the potential of our manufacturing capabilities.

About Immatics ACT Programs ACTengine is a personalized approach in which the patients own T cells are genetically modified to express a novel proprietary TCR cognate to one of Immatics proprietary cancer targets which are then reinfused back into the patient. Immatics latest proprietary ACTengine manufacturing processes are designed to generate cell product candidates within a short six day manufacturing window and to deliver highly proliferative T cells, with the capability to infiltrate the patients tumor and function in a challenging solid tumor microenvironment. The process is designed to rapidly produce younger, better-persisting T cells capable of serial killing tumor cells in vitro. Immatics is further advancing the ACT concept beyond individualized manufacturing with its product class ACTallo which is being developed to generate off-the-shelf cellular therapies.

More information on the clinical trials can be found at the following links: https://immatics.com/clinical-programs/ and https://clinicaltrials.gov/.

- ENDS - Notes to Editors

About Immatics Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

For regular updates about Immatics, visit http://www.immatics.com. You can also follow us on Twitter and LinkedIn.

About UTHealth Established in 1972 by The University of Texas System Board of Regents, The University of Texas Health Science Center at Houston (UTHealth) is Houstons Health University and Texas resource for health care education, innovation, scientific discovery and excellence in patient care. The most comprehensive academic health center in the UT System and the U.S. Gulf Coast region, UTHealth is home to Jane and Robert Cizik School of Nursing, John P. and Kathrine G. McGovern Medical School and schools of biomedical informatics, biomedical sciences, dentistry and public health. UTHealth includes The University of Texas Harris County Psychiatric Center, as well as the growing clinical practices UT Physicians, UT Dentists and UT Health Services. The universitys primary teaching hospitals are Memorial Hermann-Texas Medical Center, Childrens Memorial Hermann Hospital and Harris Health Lyndon B. Johnson Hospital. For more information, visit http://www.uth.edu.

About the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory, which is part of the Cellular Therapy Core at UTHealth, has been Immatics manufacturing partner since 2015. The site is a U.S. Food and Drug Administration (FDA)-registered and inspected cGMP facility that has received accreditation from the Foundation for Accreditation of Cellular Therapy (FACT) as well as certification from the Clinical Laboratory Improvement Amendment (CLIA) and the College of American Pathologists (CAP).

Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, should, expect, intend, will, estimate, anticipate, believe, predict, potential or continue, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.

Visit link:
Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth - GlobeNewswire